Search results

HR leaders and corporate benefits managers must balance organizational costs with decisions about which new tools and treatments will be covered by their employee health insurance plans. Getting it right can mean the difference between life and death for cancer patients. Most HR leaders, however, are not experts in cancer treatment and do not know how to make sure their plan benefits do not create roadblocks to treatment.

A total of 295 people who were diagnosed with cancer from 2019 to 2022 participated in the 2023 CancerCare Biomarker Survey, which was conducted in January 2023.

CancerCare’s 2023 survey of cancer patients found that biomarker testing helped doctors tailor therapy for nearly all the patients (93%) whose cancers were tested over the past three years. Two in 10 cancer patients (20%) avoided unnecessary chemotherapy and/or radiation and one in 10 (10%) became eligible for a clinical trial because of biomarker testing.

Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. Despite the significant and demonstrable benefits to surveyed patients, three out of 10 respondents (29%) who received biomarker testing did not have the test covered by their insurance. Some survey respondents reported that biomarker test coverage was originally denied and they had to fight to get it covered. Others had to find ways to pay out-of-pocket or seek financial assistance to cover the cost of the testing.

Unfortunately, health insurance plans often limit cancer patients’ access to recommended biomarker testing, impose burdensome prior authorization (PA) protocols or require unaffordable cost-sharing, which can prevent or delay cancer patients’ access to optimal treatments. PA, a significant source of roadblocks to timely testing and treatment, was required by a quarter (25%) of the cancer patients surveyed.

Biomarker testing is increasingly a health care equity issue and there are significant gaps in the rate of biomarker testing between black and white lung and colorectal cancer patients, which can lead to disparities in clinical trial participation and hinder access to the most effective treatments. A key way to address these barriers is to broaden insurance coverage of biomarker testing, as recommended by medical experts.

The purpose of this paper is to present information from the Joint Health and Social Care Self-Assessment Framework (JHSCSAF) on reported rates of cervical cancer, breast cancer and bowel cancer screening for eligible people with learning disabilities in England in 2012/2013 compared to screening rates for the general population.

Between 94 and 101 Learning Disability Partnership Boards, as part of the JHSCSAF, provided information to allow the calculation of rates of cervical cancer, breast cancer and bowel cancer screening in their locality, for eligible people with learning disabilities and for the population as a whole.

At a national level, reported cancer screening coverage for eligible people with learning disabilities was substantially lower than for the population as a whole (cervical cancer screening 27.6 per cent of people with learning disabilities vs 70 per cent of total population; breast cancer screening 36.8 per cent of people with learning disabilities vs 57.8 per cent of total population; bowel cancer screening 28.1 per cent of people with learning disabilities vs 40.5 per cent of the general population). There were considerable geographical variations in reported coverage for all three screening programmes.

Consistent with previous research, localities in England report cancer screening rates for eligible people with learning disabilities considerably below those of the general population. There is an urgent need to address data availability and quality issues, as well as reasonable adjustments to cancer screening programmes to ensure uniformly high rates of cancer screening for people with learning disabilities across England.

Primary care cancer lead clinicians (PCCLs) act strategically in primary care trusts (PCTs) in England to improve communication and understanding of cancer across primary and secondary care and provide a link between Cancer Networks and primary care. The aim is to evaluate the first three years of the initiative.

A postal questionnaire was sent to all PCT chief executives in all PCTs in England and some were passed on to other PCT managers for completion. The response rate was 61 per cent. PCT directors of public health were the largest group of respondents (29 per cent). Most (74 per cent) PCCLs were GPs and 22 per cent were nurses.

PCCLs were most likely to focus on palliative care and preventive services. Key achievements were identified as raising awareness of cancer, developing relationships and promoting primary care. The personal skills of the PCCLs were important as was support of colleagues at all levels. Lack of time was a major barrier to achievement, as was a lack of understanding of the role from others. Links with the Cancer Networks were being developed. About 85 per cent of managers wanted the role to continue.

The paper illustrates that PCCLs are at the forefront of improving cancer services in primary care. They are particularly important in view of the priority of reducing premature deaths and promotion of healthy lifestyles.

To gain a better understanding of the importance of the control of cancer, one must first know and understand certain basic facts about the disease. Cancer is the uncontrolled growth of malignant cells. Cancer detection tests determine whether neoplasms (new, abnormal cells) are benign (non‐cancerous) units, or malignant, health‐threatening growths. Of the hundreds of known cancers, there are four types principally affecting humans: sarcoma, cancer of connective tissue and muscles; carcinoma, cancer of lining tissues; leukemia, cancer of blood‐forming tissue; and lymphoma, cancer of lymphatic tissue. Detailed scientific and medical information on cancer can be found in texts written by authorities such as Ruddon (1981).

The purpose of this paper is to provide suggestions regarding how cancer resource center directors, staff and volunteers may encourage men battling cancer, as well as male cancer survivors, to patronize cancer resource centers and to participate in center services.

This paper provides a personal viewpoint based on research and on the author’s managerial experiences with cancer resource center services, including planning services and programming.

This paper offers cancer resource center directors suggestions regarding how they can attract male cancer patients to their organizations and encourage their participation in center services.

No limitations were identified.

This paper provides possible strategies for overcoming barriers to access to cancer resource centers in the male cancer-survivor population.

Given the medical costs associated with cancer care, encouraging men with cancer to actively participate in cancer resource center programming, which profoundly influences their physical, mental, social and spiritual well-being, can yield many societal benefits.

Cancer resource centers desire to be inclusive of all cancer patients, regardless of gender; however, these centers tend to be disproportionally patronized by women with cancer. This viewpoint addresses how this problem may be addressed via service enhancement, service programming and service design to encourage greater usage by men.

Worldwide, there are over six million new cancer cases and more than four million cancer deaths each year. Today, millions of people in the workforce have a history of cancer. Therefore, employers are seeing incidents of cancer among their employees. Many cancer survivors experience discrimination because of their cancer history. How to protect employees with cancer and what are their legal rights become very important to both employees and employers.

Cancer discussion is perceived as a taboo subject among different cultures and societies including Africans. This perception has caused limited knowledge about the disease and prevented some from seeking early diagnosis and treatment. With West Africans now living in western societies where cancer is openly discussed, this study aims to explore how black Africans perceive the disease and the implications for healthcare.

Five focus groups of 53 persons from Ghanaian and Nigerian migrant communities in Luton participated in this study.

Perceptions of fear, shame and denial were identified as key elements of how people perceive and react to cancer among the study population.

Secrecy and apprehension were identified as major barriers and have prevented some from adequately accessing and utilizing cancer facilities in the country. The feelings of fear, secrecy and stigma associated with the disease across different ethnic groups, cultures and nations also exist among the study population. These outcomes are similar and chime with published findings of limited cancer perception research among other ethnic groups and races here in the UK and across the globe.

This paper provides an overview on the links among diet, obesity and cancer prevention. It also highlights a study which confirms that following specific diet and health recommendations can help prevent cancer.

Literature searches were conducted to find the most up‐to‐date and relevant literature on diet, obesity and cancer to be included in this paper.

The World Cancer Report predicts that worldwide new cases of cancer will increase by 50 per cent by 2020 and will present a huge challenge for health and cancer support services. However, it is estimated that eating healthily, staying physically active and maintaining a healthy body weight could reduce cancer risk by 30–40 per cent. Evidence suggests that a plant‐based diet including fibre rich foods and a wide range of vitamins and minerals may offer cancer protection, while obesity and low levels of physical activity may increase cancer risk. In 1997 World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR) produced a pioneering international report: Food Nutrition and the Prevention of Cancer: A Global Perspective. The report drew attention to several links between diet and cancer prevention, and made diet and health recommendations to guide health policy and help reduce cancer risk. Adhering to these guidelines has now been shown to predict risk of and mortality from cancer. WCRF/AICR are compiling a second report which will systematically review published research on food, nutrition (including obesity), physical activity and cancer prevention. Also included will be the new and emerging area of nutrition and lifestyle factors for cancer survivors.

Information is presented to give non‐experts a general, up‐to‐date overview on the links between diet, obesity and cancer prevention.

Outlines the main proven dietary links for various forms of cancer – breast, colorectal, lung, prostate, bladder, gastric, cervical and ovarian, endometrial, pancreatic, oesophageal, laryngeal, oral and pharyngeal, testicular and melanoma. Provides some practical dietary advice in line with the UK Government’s recommendations.

The All India Institute of Medical Sciences (AIIMS) is a premier medical institution in India that has significantly contributed to cancer research. This study aims to highlight the cancer research productivity of AIIMS by assessing the impact and reach of the institution’s research output.

The study was based on 2,078 published papers on cancer of AIIMS indexed in the Web of Science (WoS) database from 1989 to 2021. A combination of tools such as Microsoft Excel, Biblioshiny, BibExcel and VOSviewer was used to evaluate and visualize the selected data.

The analysis revealed the interdisciplinary nature of research outputs, which have collaborative contributions from various fields such as oncology, pathology, radiology and surgery. The most productive research area within cancer was found to be breast cancer. In terms of international collaboration, the analysis revealed that AIIMS has a strong presence in the global cancer research community, with collaborations with researchers from more than 50 countries.

This study has some limitations. First, the study is limited to using only the WoS Core Collection database. Other databases, such as Scopus and PubMed, were excluded. Second, there is ambiguity in author names and nonuniformity in the institutions’ names, which can significantly affect the study’s outcomes.

Identifying research productivity in cancer at AIIMS aids resource allocation, collaboration and strategic planning, enhancing India’s overall cancer research impact and patient outcomes.

To the best of the authors’ knowledge, this study is to use scientometric indicators to evaluate AIIMS’s research productivity with particular reference to cancer for the first time. This detailed analysis provides a deeper understanding of AIIMS’s contribution to cancer research and its potential implications.